These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16217280

  • 1. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
    Davies B, Chen J, Modugno F, Weissfeld J, Landsittel D, Dhir R, Nelson J, Getzenberg RH.
    J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
    [Abstract] [Full Text] [Related]

  • 2. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N.
    Urol J; 2009 Nov; 6(2):101-8. PubMed ID: 19472128
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
    Davies B, Chen JJ, McMurry T, Landsittel D, Lewis N, Brenes G, Getzenberg RH.
    Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
    [Abstract] [Full Text] [Related]

  • 4. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
    Dong ZL, Lu ZP, Wang HZ, Zhang LY, Wang ZP, Zhang YF, Ma BL.
    Urol Int; 2011 Oct; 87(4):445-9. PubMed ID: 22056470
    [Abstract] [Full Text] [Related]

  • 5. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
    Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y.
    J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
    [Abstract] [Full Text] [Related]

  • 6. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C, Wiesner C, Melchior S, Gillitzer R, Schmidt F, Thüroff JW.
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [Abstract] [Full Text] [Related]

  • 7. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
    Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O.
    J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
    [Abstract] [Full Text] [Related]

  • 8. Lack of progress in early diagnosis of bladder cancer.
    Araki M, Nieder AM, Manoharan M, Yang Y, Soloway MS.
    Urology; 2007 Feb; 69(2):270-4. PubMed ID: 17320662
    [Abstract] [Full Text] [Related]

  • 9. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [Abstract] [Full Text] [Related]

  • 10. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
    Eissa S, Shabayek MI, Ismail MF, El-Allawy RM, Hamdy MA.
    IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
    [Abstract] [Full Text] [Related]

  • 14. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [Abstract] [Full Text] [Related]

  • 15. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
    Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y.
    Cancer; 2007 Mar 15; 109(6):1106-13. PubMed ID: 17311310
    [Abstract] [Full Text] [Related]

  • 16. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA, Leite KR, Sousa-Canavez JM, Camara-Lopes LH, Srougi M.
    J Urol; 2009 Feb 15; 181(2):594-600. PubMed ID: 19084862
    [Abstract] [Full Text] [Related]

  • 17. Bladder neck preservation during radical retropubic prostatectomy and postoperative urinary continence.
    Razi A, Yahyazadeh SR, Sedighi Gilani MA, Kazemeyni SM.
    Urol J; 2009 Feb 15; 6(1):23-6; discussion 26. PubMed ID: 19241337
    [Abstract] [Full Text] [Related]

  • 18. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM, Orntoft TF.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
    Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK.
    J Urol; 2006 Jun 01; 175(6):2312-6. PubMed ID: 16697865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.